DK1581193T3 - Biologisk nedbrydeligt øjenimplantat - Google Patents

Biologisk nedbrydeligt øjenimplantat

Info

Publication number
DK1581193T3
DK1581193T3 DK04700611.9T DK04700611T DK1581193T3 DK 1581193 T3 DK1581193 T3 DK 1581193T3 DK 04700611 T DK04700611 T DK 04700611T DK 1581193 T3 DK1581193 T3 DK 1581193T3
Authority
DK
Denmark
Prior art keywords
eye implant
ocular region
biodegradable
biodegradable eye
implants
Prior art date
Application number
DK04700611.9T
Other languages
English (en)
Inventor
Thierry Nivaggioli
Lin Peng
David Chou
David Weber
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of DK1581193T3 publication Critical patent/DK1581193T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • A61K9/0051Ocular inserts, ocular implants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/204Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Prostheses (AREA)
DK04700611.9T 2003-01-09 2004-01-07 Biologisk nedbrydeligt øjenimplantat DK1581193T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/340,237 US20040137059A1 (en) 2003-01-09 2003-01-09 Biodegradable ocular implant
PCT/US2004/000351 WO2004062649A2 (en) 2003-01-09 2004-01-07 Biodegradable ocular implant

Publications (1)

Publication Number Publication Date
DK1581193T3 true DK1581193T3 (da) 2012-06-25

Family

ID=32711277

Family Applications (5)

Application Number Title Priority Date Filing Date
DK08002892.1T DK1917957T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat
DK14165593.6T DK2799064T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat
DK17188114.7T DK3305284T3 (da) 2003-01-09 2004-01-07 Bionedbrydelig øjeimplantat
DK16198417.4T DK3187177T3 (da) 2003-01-09 2004-01-07 Bionedbrydeligt øjenimplantat
DK04700611.9T DK1581193T3 (da) 2003-01-09 2004-01-07 Biologisk nedbrydeligt øjenimplantat

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DK08002892.1T DK1917957T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat
DK14165593.6T DK2799064T3 (da) 2003-01-09 2004-01-07 Bioeroderbart øjenimplantat
DK17188114.7T DK3305284T3 (da) 2003-01-09 2004-01-07 Bionedbrydelig øjeimplantat
DK16198417.4T DK3187177T3 (da) 2003-01-09 2004-01-07 Bionedbrydeligt øjenimplantat

Country Status (21)

Country Link
US (1) US20040137059A1 (da)
EP (6) EP1917957B1 (da)
JP (1) JP4223040B2 (da)
KR (1) KR20050099008A (da)
CN (2) CN100364514C (da)
AT (1) ATE555779T1 (da)
AU (1) AU2004204744B2 (da)
BR (2) BRPI0406692A (da)
CA (1) CA2512315C (da)
CY (4) CY1118431T1 (da)
DK (5) DK1917957T3 (da)
ES (5) ES2384875T3 (da)
FR (1) FR12C0067I1 (da)
HK (1) HK1084021A1 (da)
HU (4) HUE036209T2 (da)
MX (1) MXPA05007342A (da)
NZ (1) NZ540451A (da)
PT (4) PT3305284T (da)
SI (3) SI3187177T1 (da)
TR (2) TR201802793T4 (da)
WO (1) WO2004062649A2 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US20050048099A1 (en) * 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
EP1633320A2 (en) 2003-05-02 2006-03-15 SurModics, Inc. Implantable controlled release bioactive agent delivery device
US7125908B2 (en) * 2003-08-29 2006-10-24 Allergan, Inc. Treating pain using selective antagonists of persistent sodium current
US7060723B2 (en) 2003-08-29 2006-06-13 Allergan, Inc. Treating neurological disorders using selective antagonists of persistent sodium current
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
WO2005072701A1 (en) 2004-01-20 2005-08-11 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US20050244472A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
KR20070095921A (ko) * 2004-12-10 2007-10-01 탈리마 테라퓨틱스 인코포레이티드 조갑 단위의 상태를 치료하기 위한 조성물 및 방법
US20060275230A1 (en) 2004-12-10 2006-12-07 Frank Kochinke Compositions and methods for treating conditions of the nail unit
AU2011236024B2 (en) * 2005-03-01 2013-05-23 Allergan, Inc. Microimplants for ocular administration
US20060204548A1 (en) * 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20090082321A1 (en) * 2007-09-21 2009-03-26 Allergan, Inc. Steroid containing drug delivery systems
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
EP1917971A1 (en) * 2006-10-27 2008-05-07 Société de Conseils de Recherches et d'Applications Scientifiques ( S.C.R.A.S.) Substained release formulations comprising very low molecular weight polymers
US8969415B2 (en) * 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
CA2680831A1 (en) * 2007-03-14 2008-09-18 University Of Washington Device and method for intraocular drug delivery
US20080317805A1 (en) * 2007-06-19 2008-12-25 Mckay William F Locally administrated low doses of corticosteroids
KR101571434B1 (ko) * 2007-09-07 2015-11-24 마티 테라퓨틱스 인코포레이티드 치료 약제의 서방성 약물 코어
US8353862B2 (en) 2007-11-02 2013-01-15 Allergan, Inc. Drug delivery systems and methods
US8524267B2 (en) * 2008-04-18 2013-09-03 Warsaw Orthopedic, Inc. Dexamethasone formulations in a biodegradable material
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US10588855B2 (en) 2008-05-12 2020-03-17 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CN102026599A (zh) 2008-05-12 2011-04-20 犹他大学研究基金会 眼内药物递送装置及相关方法
WO2009143288A1 (en) * 2008-05-20 2009-11-26 Yale University Biodegradable sustained-release polymeric microparticulates comprising a hydrophobic drug and determined for ophthalmic use
US20110206773A1 (en) * 2008-05-20 2011-08-25 Yale University Sustained delivery of drugs from biodegradable polymeric microparticles
CN101612111B (zh) * 2008-06-24 2011-11-23 上海医药工业研究院 醋酸诺美孕酮或其类似物的缓释微球及其制备方法和用途
US10842669B2 (en) 2008-11-13 2020-11-24 Gholam A. Peyman Ophthalmic drug delivery method
US10272035B2 (en) 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US20100204325A1 (en) * 2009-02-11 2010-08-12 Allergan, Inc. Valproic acid drug delivery systems and intraocular therapeutic uses thereof
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303757A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
CA2771289A1 (en) * 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using galanin retargeted endpeptidases
WO2011020119A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
WO2011020115A2 (en) 2009-08-14 2011-02-17 Allergan, Inc. Methods of treating cancer using growth factor retargeted endopeptidases
US20110070215A1 (en) 2009-08-14 2011-03-24 Allergan, Inc. Methods of treating cancer using neurotrophin retargeted endopeptidases
CN102573875A (zh) 2009-08-14 2012-07-11 阿勒根公司 使用速激肽再靶向内肽酶治疗癌症的方法
KR20120107926A (ko) 2009-08-14 2012-10-04 알러간, 인코포레이티드 오피오이드 재표적화된 엔드펩티다아제를 사용하여 암을 치료하는 방법
CA2789151A1 (en) 2010-02-08 2011-08-11 Allergan, Inc. Pyridazine derivatives useful as cannabinoid-2 agonists
US20130030055A1 (en) 2010-03-24 2013-01-31 Allergan, Inc. Compositions and methods for treating hair loss, hair thinning, and hair color loss
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US20120207704A1 (en) 2011-02-14 2012-08-16 Allergan, Inc. Inhibiting Aberrant Blood Vessel Formation Using Growth Factor Retargeted Endopeptidases
WO2012112432A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Methods of inhibiting aberrant blood vessel formation using opioid retargeted endopeptidases
WO2012112420A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Treatments using psma ligand endopeptidases
WO2012112426A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Arginine vasopressin retargeted clostridial endopeptidases for use in treating benign prostatic hyperplasia
WO2012112434A1 (en) 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
US9308355B2 (en) 2012-06-01 2016-04-12 Surmodies, Inc. Apparatus and methods for coating medical devices
WO2014066644A1 (en) 2012-10-26 2014-05-01 Allergan, Inc. Ketorolac-containing sustained release drug delivery systems
CN112932781A (zh) * 2013-01-15 2021-06-11 科罗拉多州立大学董事会, 公司实体 泪腺系统给药装置
CN105377355A (zh) 2013-03-14 2016-03-02 拇趾公司 治疗甲单元的感染、疾病或病症的方法
CN110302138B (zh) * 2013-10-31 2022-09-30 阿勒根公司 含前列腺酰胺的眼内植入物及其使用方法
AU2015223010A1 (en) * 2014-02-26 2016-09-15 Allergan, Inc. Intraocular implant delivery apparatus and methods of use thereof
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
RU2687176C2 (ru) 2014-09-11 2019-05-07 Айпоинт Фармасьютикалз Юэс, Инк. Инъекционное устройство
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
WO2017053885A1 (en) 2015-09-25 2017-03-30 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
USD851755S1 (en) 2015-10-22 2019-06-18 Eyepoint Pharmaceuticals Us, Inc. Ocular inserter
WO2017091404A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of Colorado, A Body Corporate Lacrimal system for drug delivery
CN115120405A (zh) 2016-04-20 2022-09-30 多斯医学公司 生物可吸收眼部药物的递送装置
EP3458030B1 (en) 2016-05-20 2021-05-12 The Regents of The University of Colorado, A Body Corporate Lacrimal drug delivery device
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
US20210060316A1 (en) * 2019-08-30 2021-03-04 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322323A (en) * 1980-12-01 1982-03-30 Alza Corporation Erodible device comprising surfactant for modifying the rate of erosion of the device
EP0052916B1 (en) * 1980-11-10 1985-01-02 Alza Corporation Erodible polymer containing erosion rate modifier
US4883457A (en) * 1983-08-18 1989-11-28 Drug Delivery Systems Inc. Disposable and/or replenishable transdermal drug applicators and methods of manufacturing same
US6217911B1 (en) * 1995-05-22 2001-04-17 The United States Of America As Represented By The Secretary Of The Army sustained release non-steroidal, anti-inflammatory and lidocaine PLGA microspheres
US6309669B1 (en) * 1984-03-16 2001-10-30 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive materials encapsulated within a biodegradable-biocompatible polymeric matrix
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
JPS63291419A (ja) * 1987-05-24 1988-11-29 Tatsumo Kk 加熱処理装置
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
KR0185215B1 (ko) * 1990-11-30 1999-05-01 요시다 쇼오지 서방성 안구삽입용 약제
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5707643A (en) * 1993-02-26 1998-01-13 Santen Pharmaceutical Co., Ltd. Biodegradable scleral plug
DE69425411T2 (de) 1993-02-26 2001-02-08 Santen Pharmaceutical Co., Ltd Biologisch abbaubarer sklerastopfen
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US6369116B1 (en) * 1995-06-02 2002-04-09 Oculex Pharmaceuticals, Inc. Composition and method for treating glaucoma
EP0817619A4 (en) * 1996-01-24 1999-02-03 Us Army NEW POLY- (LACTIDE / GLUCOLIDE) MICROSPHERES WITH EXTENDED RELEASE "WITHOUT BREAKING"
KR20010014384A (ko) * 1997-07-02 2001-02-26 모리타 다카카즈 폴리락트산 공막 플러그
US6306426B1 (en) * 1997-08-11 2001-10-23 Allergan Sales, Inc. Implant device with a retinoid for improved biocompatibility
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6726918B1 (en) * 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
WO2002043785A2 (en) * 2000-11-29 2002-06-06 Oculex Pharmaceuticals, Inc. Intraocular implants for preventing transplant rejection in the eye

Also Published As

Publication number Publication date
HUE044694T2 (hu) 2019-11-28
TR201802793T4 (tr) 2018-03-21
CA2512315A1 (en) 2004-07-29
PT1917957T (pt) 2017-01-23
CA2512315C (en) 2008-12-30
DK3305284T3 (da) 2019-08-19
WO2004062649A3 (en) 2004-11-04
CY1121731T1 (el) 2020-07-31
HK1084021A1 (en) 2006-07-21
ES2742152T3 (es) 2020-02-13
DK1917957T3 (da) 2017-02-13
JP4223040B2 (ja) 2009-02-12
CY1118431T1 (el) 2017-06-28
EP3187177B1 (en) 2019-03-20
CN101259280A (zh) 2008-09-10
EP3305284B1 (en) 2019-05-15
FR12C0067I1 (fr) 2012-12-14
EP2799064B1 (en) 2017-11-29
ES2735132T3 (es) 2019-12-16
AU2004204744B2 (en) 2008-03-13
US20040137059A1 (en) 2004-07-15
HUE036209T2 (hu) 2018-06-28
CY1120147T1 (el) 2018-12-12
PT2799064T (pt) 2018-03-06
ATE555779T1 (de) 2012-05-15
HUE044965T2 (hu) 2019-11-28
EP2799064A1 (en) 2014-11-05
EP1917957A2 (en) 2008-05-07
HUE030319T2 (en) 2017-05-29
EP1917957A3 (en) 2011-06-15
CN1735405A (zh) 2006-02-15
ES2384875T3 (es) 2012-07-13
KR20050099008A (ko) 2005-10-12
BR122015016901B1 (pt) 2018-06-05
BRPI0406692A (pt) 2005-12-20
PT3187177T (pt) 2019-06-27
EP3305284A1 (en) 2018-04-11
EP1581193A2 (en) 2005-10-05
JP2006525953A (ja) 2006-11-16
EP1581193B1 (en) 2012-05-02
MXPA05007342A (es) 2005-09-30
CY1121912T1 (el) 2020-10-14
EP3187177A1 (en) 2017-07-05
ES2661383T3 (es) 2018-03-28
WO2004062649A2 (en) 2004-07-29
ES2613028T3 (es) 2017-05-22
SI2799064T1 (en) 2018-04-30
EP1917957B1 (en) 2016-11-16
AU2004204744A1 (en) 2004-07-29
DK2799064T3 (da) 2018-03-12
SI3187177T1 (sl) 2019-09-30
DK3187177T3 (da) 2019-06-24
TR201908857T4 (tr) 2019-07-22
PT3305284T (pt) 2019-08-30
NZ540451A (en) 2008-02-29
CN100364514C (zh) 2008-01-30
SI3305284T1 (sl) 2019-11-29
EP3563839A1 (en) 2019-11-06
BR122015016901B8 (pt) 2021-07-27

Similar Documents

Publication Publication Date Title
CY1121731T1 (el) Βιοαποικοδομησιμο οφθαλμικο εμφυτευμα
TW200621263A (en) Ocular implant made by a double extrusion process
WO2002043785A3 (en) Intraocular implants for preventing transplant rejection in the eye
WO2006002366A3 (en) Biodegradable ocular devices, methods and systems
WO2006014484A3 (en) Methods and devices for the treatment of ocular conditions
WO2005110436A3 (en) Macromolecule-containing sustained release intraocular implants and related methods
ATE404140T1 (de) Vorrichtung zur intraokularen wirkstoffverabreichung
WO2004087006A3 (en) Implant delivery technologies
JP2014128739A5 (da)
WO2010059214A3 (en) Biocompatible biodegradable intraocular implant system
WO2005034852A3 (en) Protein biomaterials and biocoacervates and methods of making and using thereof
MX2009005405A (es) Sistemas intraoculares de distribucion de farmaco.
BRPI0712194A2 (pt) Implantes pélvico e cirúrgico combinação ferramenta cirúrgica útil para implantar um implante pélvico métodos de tratamento de uma condição pélvica, e de prolapso vaginal, e, método para manipular um implante cirúrgico
WO2007076508A3 (en) Implantable graft material
TW200603838A (en) Extended release biodegradable ocular implants
WO2004069335A3 (en) Magnetic implants to treat body tissue structures
MX2011008875A (es) Implantes lagrimales y metodos relacionados.
WO2007130134A3 (en) Controlled release microparticles
EP1621219A3 (en) Intraocular implants for preventing transplant rejection in the eye
CA2567140A1 (en) Methods and apparatus for delivery of ocular implants
UA40313A (uk) Спосіб видалення підвивихнутого кришталика з наступною імплантацією штучного кришталика